STUDresearch · Peptide

Semaglutide

Also known as

Ozempic · Wegovy · Rybelsus · Sema · Semaglutide acetate (research/compounded discussions) · Semaglutide sodium (research/compounded salt form — FDA concern) · NN9535 (developmental designation, historical) · GLP-1 RA / weekly GLP-1

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗

Peptide Lots of talk Systemic SubQ / Oral Metabolic / GLP-1 class

Whole-body — appetite and stomach-emptying, not a local fat pin.

What people say Semaglutide is a GLP-1 medicine people discuss for quieter appetite and less food noise, not a stimulant-like fat-loss feeling.Weekly injections and daily tablets have different product and absorption contexts. Doses people talk about

Lower weekly discussion0.25–1 mg SC per week

Stay-low, microdose and slow-hold cultures remain in the full notes; responses include early benefit, fading effect and nonresponse.

Wegovy injection — indication-specific1.7 or 2.4 mg weekly; 7.2 mg adult-weight option

The 7.2 mg option follows tolerated 2.4 mg in adult weight treatment, not every age or indication.

Ozempic injection — diabetes context0.5, 1 or 2 mg SC weekly

Distinct from the 0.25 mg tolerability initiation and from Ozempic tablets.

Daily oral maintenance — distinct productsRybelsus 7/14 mg; Ozempic tablets 4/9 mg; Wegovy 25 mg

Separate formulations and indications, not mg-for-mg substitutes. Initiation strengths and food rules stay in the full notes.

Reported or labeled amounts, not a starting or step-up plan. Oral and injected milligrams are not interchangeable; vial units depend on concentration.

Half-life & effect duration

Half-life in the body: Ozempic injectionAbout 1 week
Other oral / injected study estimatesAbout 160–183 hours — roughly 1 week
Felt duration people report: One appetite accountHunger returned the day before the next shot, with occasional hunger days at other times
Other community reportsStrongest curb on days 1–3, or more even mid-week control

Timing context & sources

How it may feel Reported early experiences include less appetite, nausea, sulfur burps—or no obvious change. Responses differ over a course of use.

Cycles people discuss Discussion centers on ongoing use and maintenance, not a fixed short on/off cycle. People also describe appetite returning during breaks. Timing A regular weekly routine, often the same weekday, dominates injection discussion. Hours vary; some choose evening because of nausea. Oral products have different food and absorption considerations. Stacks Protein + resistance training: Primary non-drug stack against lean-mass loss and “Ozempic face” talk. Access talk Three shelves people mix up: branded products (Ozempic / Wegovy / Rybelsus), patient-specific 503A compound when a prescriber documents a clinical difference, and research-use-only vials that were never the pharmacy path. Watch for GI (most common): Nausea, vomiting, diarrhea, constipation, abdominal pain, bloating, burping/sulfur burps.

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

About 1 week for subcutaneous Ozempic.

This is the decline in circulating semaglutide, not a promise of constant appetite suppression.

The label also describes persistence in circulation for about 5 weeks after the last dose; that is not five weeks of constant subjective effects.

Ozempic prescribing information (opens in a new tab)May 2026 revision, printed page 5, section 12.3, EliminationSubcutaneous Ozempic labeling; this source does not verify every compounded or oral formulation or predict felt duration.

Felt duration people report

One user describes hunger returning the day before the next shot, plus occasional hunger days at other times.

A variable appetite report during repeated use—not a fixed duration after a single dose.

Dose, food, treatment stage and formulation can differ between people. This report does not measure clearance or establish how long everyone will feel an effect.

Hunger days? — community discussion (opens in a new tab)Comment describing seven months of use, hunger the day before the shot and occasional unrelated hunger daysIndividual self-report; brand, formulation and objective exposure were not established. No prevalence or causal estimate.

Other context in this card

Current Wegovy: product-specific dose and risk context (opens in a new tab)June 2026 U.S. label §§2.2–2.3, 6.1, 12.3: indication-specific SC maintenance, tablet strengths, dysesthesia and formulation PK. Acting and independent actual content inspection September 6.U.S. labeled products and trial populations, not verification of compounded or research products.
Rybelsus and Ozempic tablets: distinct formulations (opens in a new tab)Current Rybelsus/Ozempic tablet label §§2, 3, 12.3: distinct strengths, no mg-for-mg substitution and separate absorption estimates. Independent actual content inspection September 6.Product-specific oral amounts and absorption, not substitutes for injected milligrams.
Semaglutide: lower-amount response and nonresponse (opens in a new tab)ForCryingInTheCorn opening/replies; Arborecat, Sarafina908, Bitter_Indication_66, Vivid-Birthday940 comments. Actual post/comment content read independently September 6.Different individuals report 0.25/0.5 mg experiences; preserve existing notes for the wider 0.25–1 mg range. No prevalence, product verification or personal schedule.

What people say 13

Food noise: Users widely report less constant food thinking and easier portion control within the first weeks. forum
Alcohol-noise (unexpected): A loud minority say drink-thinking dropped with food-thinking — not a labeled use; hangover and “one drink wrecks me” stories run the other way. forum
Weight (STEP 1): Mean −14.9% body weight at 68 weeks on 2.4 mg weekly SC vs −2.4% placebo (+ lifestyle). trial
Responders (STEP 1): ~86% hit ≥5% loss; ~69% ≥10%; ~50% ≥15% at 68 weeks on 2.4 mg. trial
STEP 5 (2 years): Mean ~−15.2% at 104 weeks on continued 2.4 mg vs ~−2.6% placebo — maintenance while on drug. trial
Glucose (T2D): SUSTAIN / Ozempic programs show meaningful HbA1c drops at 0.5–1–2 mg weekly. trial
Satiety / emptying: Mid-meal fullness, less snacking, delayed gastric emptying drive intake cut and some nausea. trial
Cardiometabolic markers: Waist, BP, lipids, CRP improvements track weight loss in STEP. trial
vs liraglutide: Stronger average weight effect with weekly SC vs daily liraglutide 3.0 mg (STEP 8-class comparisons). trial
vs tirzepatide: Dual GIP/GLP-1 often shows greater mean weight loss at studied high doses — common switch discussion. trial
Oral option: Rybelsus daily tablet for needle-averse users; absorption rules differ from SC and mg is not 1:1. trial
On-drug hold: Continued weekly therapy holds much of the loss; stopping predicts substantial regain in extensions. trial
Trial-product estimand: On-treatment mean loss closer to ~−16.9% vs −2.4% placebo in STEP 1 secondary framing. trial

Doses people talk about 19

mcg translation: 0.25 mg = 250 mcg; 0.5 = 500 mcg; 1.0 = 1000 mcg; 1.7 = 1700 mcg; 2.4 = 2400 mcg weekly. forum
Compounded vial talk: Often mirrors brand titration (0.25→0.5→1.0→~1.7–2.4 mg weekly); concentrations vary by pharmacy. forum
Research-vial start talk: Common community starts 250 mcg weekly; some microdose 50–125 mcg weekly before 0.25 mg. forum
Split dosing (anecdotal): Some split weekly total into 2×/week half-doses (e.g., 0.125 mg twice) to blunt peak GI; PK still long-acting. anecdote
Dose camps people actually compare: (1) copy the full Wegovy climb to 2.4, (2) park forever at 0.5–1.0 once food noise dies, (3) micro / stay-0.25 aesthetic camp. Same molecule, three cultures. forum
Pharmacy-unit trap: Compounded “units” are not a universal mg — 2026 switch threads warn you cannot copy 20 units from one vial to the next without the new concentration. forum
Community titration pattern: Still the loudest pattern: start low weekly SC, step up every ~4 weeks if GI allows (0.25 → 0.5 → 1.0 → higher maintenance bands people copy from labels). forum
Microdosing / stay-low: Hold 0.25–0.5–1.0 mg long-term for food noise with fewer sides — not a labeled “micro” product. forum
Slow titration variants: Hold a step 6–8+ weeks, skip a rung, or never climb to 2.4 mg if appetite already controlled. forum
Microdose camp: Some run below label obesity max for “food noise only” with fewer sides — contested and not a labeled wellness dose. forum
Wegovy weekly ladder (weight): 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg SC once weekly; ~4-week steps to minimize GI. trial
Oral Rybelsus (daily): 3 mg ×30 days → 7 mg; may escalate to 14 mg daily max; empty-stomach rules mandatory. Newer U.S. Ozempic tablets use 1.5/4/9 mg strengths; Wegovy tablets use 1.5/4/9/25 mg, with 25 mg adult maintenance. These formulations are not mg-for-mg substitutes. trial
Oral ≠ SC mg: Daily 3/7/14 mg oral is not interchangeable 1:1 with weekly SC mg because bioavailability is very low. trial
Injection sites: Abdomen, thigh, or upper arm SC; rotate sites; any time of day ± food for pens. trial
Framing: Labeled, trial, and community ranges only — research/educational discussion, not advice or a use protocol. forum
Wegovy maintenance: U.S. labeling distinguishes indications:1.7 or 2.4 mg SC weekly for weight/CV use, with 2.4 mg preferred; adult weight reduction may use 7.2 mg after at least 4 weeks tolerating 2.4 mg. MASH and pediatric options differ. This is product context, not a personal ladder. trial
Ozempic (T2D) bands: 0.25 mg ×4 weeks start → 0.5 mg → may go to 1.0 mg → up to 2.0 mg weekly max labeled. trial
Missed SC dose (class label talk): Take when remembered if several days remain until next weekly day; otherwise skip — product insert rules. trial
Salt-form uncertainty: FDA has flagged compounded products using acetate/sodium salts vs base used in approved pens. trial

How it may feel 10

Days 1–7: Mild appetite blunt, early nausea, sulfur burps, or nothing noticeable at 0.25 mg. forum
Weeks 1–4 (0.25 mg): Labeled start band for GI adaptation — many say scale moves little; food interest may already drop. forum
Weeks 5–8 (0.5 mg): Clearer intake cut for responders; first real “it works” week for many. forum
Weeks 9–12 (1.0 mg): Therapeutic for many; GI often re-flares after each step-up then settles on a hold. forum
Months 2–4: Steady weekly loss common if protein + calories aren’t collapsed; clothes-fit talk rises. forum
Months 4–6+: Plateau, hold-vs-raise dose, and “lowest effective dose” debates dominate forums. forum
First weeks vs later food noise: 0.25 mg is often “meh” for cravings; many say the quiet hits closer to 0.5–1.0. Months later, chatter creeping back on a hold gets blamed on tolerance, a pharmacy switch, or a B12-additive lot. forum
Shot-day vs end-of-week: Strongest curb often 1–3 days post-pin; late-week snackiness is the usual “is it wearing off or am I bored?” argument. forum
Weeks 13–16 (1.7 mg Wegovy path): Escalation toward weight-maintenance dose; constipation/nausea still common. trial
Week 17+ (2.4 mg Wegovy maintenance): The established 2.4 mg maintenance path, not every current indication-specific option; mean trial curves keep falling into months 4–12+. trial

Around the dose 8

Clock: Weekly, same weekday. Time of day is flexible; some pick evening so nausea sleeps. forum
Food: Protein first, smaller plates, slower eating. The shot quiets food noise; it does not chew for you. forum
Training: Lift. Muscle-loss talk is the pairing — people who only cut calories and never train are the usual “I look smaller but worse” logs. forum
After a dose: Water, walking, and not frying-food-testing gastric emptying on shot day. forum
Avoid: “Stack more appetite drugs because the first week was quiet” is a frequent side-effect thread. forum
Alcohol: Shot-week drinking is a classic nausea/reflux story; some skip or delay the pin for a dinner, then resume the weekday. Forum habit, not a protocol. forum
Protein when chewing fails: Shakes, yogurt, eggs, deli get named when solid food is gross — lifting threads treat a protein floor as the anti-“Ozempic face” habit, not extra milligrams. forum
Women-loud vs men-loud: Face-hollowing, hair-shed, and cycle/appetite-shift talk is denser in women’s groups; men more often argue training fuel and food-reward. Same drug, different complaint mix. forum

Cycles people discuss 9

Maintenance philosophy: Lowest effective weekly dose once goal weight hits is common forum advice. forum
Continuous vs off periods: Off periods not standardized; appetite rebound can erase much of the loss. forum
Restart after a break: Community accounts discuss returning at a lower step because the old higher amount can bring renewed severe GI effects. The reports do not establish a safe universal restart schedule. forum
Not a short cycle drug: Chronic weekly (or daily oral) therapy model — regain after stop is well documented. trial
On-ramp length: Full Wegovy ladder is ~16 weeks to first 2.4 mg maintenance week if every 4-week step is taken. trial
Escalation tolerance: Label discussion includes delaying escalation by about 4 weeks when poorly tolerated; dose reduction or interruption depends on the product and clinical situation, not a universal forum adjustment rule. trial
STEP 1 extension: After 68 weeks on drug then stop, mean regain ~11.6 percentage points by week 120 (~net −5.6% from baseline). trial
STEP 4 message: Switching to placebo after run-in produced regain vs continued semaglutide — supports ongoing use for hold. trial
Time-to-goal: Individual; trial means keep falling for many months — not a 4-week cut. trial

Timing 8

Steady feel: Many report more even mid-week control than short daily GLP-1s; some still feel a post-shot GI peak. forum
Half-life: ~1 week (~160–183 hours reported across SC/oral contexts) for both oral and SC semaglutide. trial
Why weekly SC: Albumin binding + DPP-4 resistance extend exposure → once-weekly injection. trial
Gastric emptying: Delayed emptying = satiety + nausea risk; also raises talk of delayed oral-drug absorption. trial
Overdose observation: Long half-life means severe GI/hypoglycemia symptoms may need prolonged observation. trial
Downstream timelines: Appetite days–weeks; scale weeks–months; cardiometabolic markers trail the weight curve. trial
Oral PK note: Rybelsus 3/7/14 mg has estimated 0.4–1% bioavailability with SNAC; current Ozempic and Wegovy tablets have 1–2% estimates. Oral absorption varies day to day and daily dosing/long half-life moderate exposure variability; it is not equivalent to SC milligrams. trial
Clearance window: Remains in circulation ~5 weeks after last dose (~5 half-lives / ~97% elimination framing). The approximately 5 week statement is Ozempic-label context; current Wegovy specifies about 5–7 weeks after 2.4/7.2 mg injection or 25 mg tablets. Neither is a clock for unchanged appetite effects. trial

Stacks 14

Protein + resistance training: Primary non-drug stack against lean-mass loss and “Ozempic face” talk. forum
Electrolytes / hydration / fiber: Common GI and constipation support when intake collapses. forum
Anti-nausea tactics: Ginger, smaller low-fat meals, prescribed anti-emetics in clinic settings (anecdotal). forum
AOD-9604 / frag: Appetite drug + “lipolytic peptide” pair — attribution heavily confounded. forum
BPC-157: Gut-interest pair when GI sides dominate; no rigorous add-on data for GLP-1. forum
CJC/Ipamorelin or MK-677: Minority GH-axis co-logs for recovery/comp — confounded. forum
Do not dual full-dose incretins: Stacking semaglutide + tirzepatide/liraglutide/reta generally discouraged (GI load, unknown add-on risk). forum
Switch paths: Sema → tirz or reta more common than true concurrent dual-GLP stacks. forum
Metformin / other T2D meds: Clinician territory; hypoglycemia and GI interaction talk. forum
Lifestyle stack: Sleep, steps, protein targets credited after the early honeymoon. forum
With training: Best logs pair the shot with lifting and protein targets, not shot-only. forum
Reta/Tirz migration: People hop to tirzepatide or retatrutide when sema stalls or sides suck — forum pattern, not a protocol. forum
B12-in-the-vial: 2026 compounding shops sold sema+B12 as a “personalized” copy workaround; users argue it feels weaker or changes the unit math — not a studied combo. forum
Cagrilintide / CagriSema context: Amylin + sema combo is a separate pharma program — not DIY stacking. trial

Access talk 8

Three shelves people mix up: branded products (Ozempic / Wegovy / Rybelsus), patient-specific 503A compound when a prescriber documents a clinical difference, and research-use-only vials that were never the pharmacy path. forum
2026 argument: “Is compounded still legal?” is often louder than the molecule — the fight is copy compounding of the pens, not whether semaglutide exists. forum
RUO migration: Clinic channel tightening pushed some talk onto research-chem vendors. A “not for human use” label is not a purity stamp. forum
Salt-form / additive fights: Acetate vs base, and B12-in-the-vial “weaker shot” stories, are 2026 quality arguments — not a new mechanism. forum
Prescription vs gray: Branded pen = labeled product + insurance/cash fight. Compounded copy = post-shortage legal squeeze. Gray powder = forum reconstitution math. Do not collapse them. forum
Shortage window closed: FDA treated the branded-injection shortage as resolved 21 Feb 2025; 503A/503B copy-compounding then wound down on a 60/90-day clock (spring 2025 dates in the enforcement notes). trial
Still-for-sale talk: 2025–26 secret-shopper writeups still found businesses offering compounded sema months after the wind-down dates, often with B12/additives billed as personalized. trial
503B bulks proposal: April 2026 FDA proposal talk would keep semaglutide off the 503B bulks list even in a future shortage — compounding forums treat that as the door-closing headline. trial

Storage notes 2

No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Related 11

Watch for 23

Escalation flares: Sides often return or worsen for days–weeks after each dose jump, then ease on a hold. In the higher-dose Wegovy adult trials, dysesthesia was reported in 22% at 7.2 mg versus 6% at 2.4 mg and 0.3% on placebo; this is not a rate for every semaglutide formulation. forumtrial
Intake collapse: Strong suppression → low food/fluids → lightheaded, constipation, fatigue, nutrient gaps. forum
Gastroparesis / severe delay: Delayed emptying is part of MOA; rare severe “stomach paralysis” reports drive litigation and forum fear. forum
Lean mass / face: “Ozempic face” and muscle-loss worry; protein + lifting repeatedly recommended. forum
Hair shedding: Often attributed to rapid weight loss / calorie deficit rather than unique peptide toxicity. forum
Dehydration / kidney stress: Vomiting/diarrhea → volume depletion talk; monitor fluids. forum
Source risk: Contamination, wrong peptide, wrong concentration, salt-form swaps, counterfeit pens. forum
Surgery / anesthesia talk: Delayed gastric emptying raises aspiration concerns before procedures — clinician hold policies vary. forum
Not risk-free: High trial evidence does not make gray-market self-experimentation safe or equivalent to labeled care. forum
Food noise tradeoff: Appetite suppression can nuke training fuel if protein isn’t deliberate — big bro complaint. forum
Muscle loss anxiety: Lifting + high protein is the standard community counter-story to “Ozempic face / soft look.” forum
Pharmacy-switch fade: Food noise returning after a compounder or additive change is a 2026 thread — confounders include tolerance, diet, and actual mg delivered. forum
RUO vendor-collapse: After clinic compounding tightened, displaced demand talk moved to “research use only / not for human consumption” vials — same name, none of the pen QC. forum
Counterfeit pens: Fake Ozempic/Wegovy pens remain a watch-for beside compounding math errors. forum
GI (most common): Nausea, vomiting, diarrhea, constipation, abdominal pain, bloating, burping/sulfur burps. trial
Gallbladder: Cholelithiasis / cholecystitis signal with rapid weight loss and GLP-1 class use. trial
Thyroid C-cell: Rodent medullary thyroid carcinoma findings → boxed caution; personal/family MTC or MEN2 history discussed as contraindication class. animal
Hypoglycemia risk: Higher when combined with insulin or sulfonylureas; less dominant as monotherapy in non-T2D. trial
Injection-site: Local reactions uncommon but possible; rotate sites. trial
Compounded overdose pattern: FDA reports of 5–20× intended dose from unit math errors → severe GI, dehydration, hospitalization. trial
Pregnancy: Labels advise discontinuation; not a research use case to explore casually. trial
Shortage-end compounding: Branded-injection shortage was treated as resolved Feb 2025; mass copy-compounding lost that exemption after the 60/90-day wind-down. Leftover clinic vials are not a free pass. trial
Pancreatitis: Label warning; severe persistent upper abdominal pain → stop and seek care framing on labels. trial

Updated: 2026-09-01

Evidence mix Mixed trial + community tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.

↑ Back to top

Half-life & effect duration

Timing context & sources⌄

Half-life in the body

Felt duration people report

Other context in this card

What people say 13

Doses people talk about 19

How it may feel 10

Around the dose 8

Cycles people discuss 9

Timing 8

More on what it is 10

Stacks 14

Access talk 8

Storage notes 2

Related 11

Watch for 23

Timing context & sources